BVS Bioventus

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

To participate in the conference call, dial 1-833-636-0497 (domestic) or (international) and refer to the Bioventus Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at . The webcast will be archived at the same site and available for replay until May 10, 2024.

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit and follow the Company on and . Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:

Dave Crawford

919-474-6787



EN
03/05/2023

Underlying

BVSBioventus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioventus

 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Reports Third Quarter Financial Results

Bioventus Reports Third Quarter Financial Results Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8%Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per diluted shareNon-GAAP earnings* of $0.15 per diluted share increased 200%Cash from operations of $30.1 million increased 192%Company reaffirms revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) --  Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Result...

Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market opens on Tuesday, November 4, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Cal...

October 28, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthca...

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025, at 1:05 p.m. ET. A live webcast of the presentation will be available on the “Investors” section of the Company’s website at and will be available for replay on that site fol...

September 3, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growt...

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the “Investors” section of the Company’s website at and will be available for...

August 7, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Reports Second Quarter Financial Results

Bioventus Reports Second Quarter Financial Results Q2 reported revenue of $147.7 million declined 2.4%; Organic* revenue advanced 6.2%Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year periodNon-GAAP earnings* of $0.21 per share increased 31%Cash from operations of $25.9 million increased 71%Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for...

August 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch